Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results , with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was ...

10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. ... However, the real profit lies in the sale of consumables, such as reagents, ...

PLEASANTON, Calif. – 10x Genomics, Inc. (NASDAQ:TXG), a company specializing in single cell and spatial biology technologies, has released preliminary financial results for the third quarter ended ...

10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. ... Consumables sales decreased from $140.31 million to $133.53 million.

10x Genomics reported Q3 2024 revenue of $151.7 million, down 1% from last year. Instruments revenue dropped 46%, while consumables grew 10%. CEO Serge Saxonov acknowledged the challenges faced ...

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems.

10x Genomics is bordering on breakeven, according to the 12 American Life Sciences analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$6 ...

10X Genomics (NASDAQ:TXG), a leading player in the genomics industry, finds itself at a crucial juncture as it navigates through a challenging macroeconomic landscape while capitalizing on the ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter ...